Cell Lines

• US 20080118479A1
• Filed: 01/28/2008
• Published: 05/22/2008
• Est. Priority Date: 09/30/2004
• Status: Active Grant

• Current Assignee: John Sinden, Kenneth Pollock, Paul Stroemer
• Original Assignee: John Sinden, Kenneth Pollock, Paul Stroemer
• Inventors: Stroemer, Paul, Pollock, Kenneth, Sinden, John
• Granted Patent: US 7,666,672 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/46 Amines, e.g. putrescine
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/392 Sexual steroids
• CPC Class Codes: C12N 2510/04 Immortalised cells
• CPC Class Codes: C12N 5/0623 Stem cells

Abstract

The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302.

Claims

1. An isolated cell obtainable from a cell line selected from the group consisting of CTX-OE03 (deposited under ECACC Accession No. 04091601), STROC05 (deposited under ECACC Accession No. 04110301), and HPCOA07 (deposited under ECACC Accession No. 04092302).

2. A pharmaceutical composition, comprising isolated cells obtainable from a cell line selected from the group consisting of CTX-OE03 (deposited under ECACC Accession No. 04091601), STROC05 (deposited under ECACC Accession No. 04110301), and HPCOA07 (deposited under ECACC Accession No. 04092302);

and

a pharmaceutically acceptable carrier.

3. A method for the manufacture of a pharmaceutical composition, comprising combining isolated cells with a pharmaceutically acceptable carrier, wherein the cells are obtainable from a cell line selected from the group consisting of CTX-OE03 (deposited under ECACC Accession No. 04091601), STROC05 (deposited under ECACC Accession No. 04110301), and HPCOA07 (deposited under ECACC Accession No. 04092302).

4. A method for the treatment of a disorder associated with cell loss or cell damage, comprising transplanting an effective amount of isolated cells into a patient, wherein the cells are obtainable from a cell line selected from the group consisting of CTX-OE03 (deposited under ECACC Accession No. 04091601), STROC05 (deposited under FCACC Accession No. 04110301), and HPCOA07 (deposited under ECACC Accession No. 04092302).

5. The method according to claim 4, wherein the disorder is ischaemia or stroke.

6. The method according to claim 4, wherein the disorder is Alzheimer'"'"'s disease.

7. The method according to claim 4, wherein the disorder is traumatic brain injury.

8. The method according to claim 4, wherein the disorder is Creutzfeld-Jacob disease.

9. A method for determining the effect of at least one biological or chemical agent on a neurological disease or disorder, comprising contacting a culture of cells with said biological or chemical agent;

and determining the effect of said biological or chemical agent on at least one of the cells, wherein the cells are obtainable from a cell line selected from the group consisting of CTX-OE03 (deposited under ECACC Accession No.

     04091601), STROC05 (deposited under ECACC Accession No.

     04110301), and HPCOA07 (deposited under ECACC Accession No.

     04092302).